Proficio Capital Partners LLC Invests $941,000 in Illumina, Inc. $ILMN

Proficio Capital Partners LLC acquired a new position in shares of Illumina, Inc. (NASDAQ:ILMN) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 5,353 shares of the life sciences company’s stock, valued at approximately $941,000.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Elyxium Wealth LLC acquired a new position in Illumina in the fourth quarter valued at about $25,000. Fiduciary Financial Advisors acquired a new position in shares of Illumina during the 2nd quarter worth about $26,000. Keating Financial Advisory Services Inc. acquired a new position in shares of Illumina during the 2nd quarter worth about $32,000. Quarry LP bought a new stake in shares of Illumina in the 3rd quarter valued at about $32,000. Finally, Nano Cap New Millennium Growth Fund L P bought a new stake in shares of Illumina in the 4th quarter valued at about $33,000. Institutional investors own 89.42% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on ILMN shares. Zacks Research raised shares of Illumina from a “hold” rating to a “strong-buy” rating in a research note on Monday, August 3rd. Stifel Nicolaus upped their target price on shares of Illumina from $155.00 to $225.00 and gave the company a “buy” rating in a research note on Friday, July 31st. Leerink Partners upped their target price on shares of Illumina from $175.00 to $210.00 and gave the company an “outperform” rating in a research note on Friday, July 17th. Guggenheim increased their target price on shares of Illumina from $200.00 to $226.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Finally, Evercore reissued an “outperform” rating on shares of Illumina in a research report on Monday, July 6th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, Illumina has a consensus rating of “Hold” and an average price target of $188.40.

Illumina Trading Down 3.0%

NASDAQ ILMN opened at $207.13 on Wednesday. The firm has a market cap of $31.28 billion, a P/E ratio of 38.64, a P/E/G ratio of 3.01 and a beta of 1.44. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40. The stock’s 50-day moving average is $195.94 and its 200-day moving average is $157.18. Illumina, Inc. has a one year low of $88.00 and a one year high of $231.81.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.23 by $0.08. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The business had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.13 billion. During the same period in the previous year, the firm earned $1.19 EPS. Illumina’s quarterly revenue was up 9.4% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Sell-side analysts anticipate that Illumina, Inc. will post 5.36 earnings per share for the current fiscal year.

Insider Buying and Selling at Illumina

In other news, SVP Christensen Jakob Wedel sold 1,033 shares of the company’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $191.52, for a total value of $197,840.16. Following the completion of the transaction, the senior vice president owned 14,023 shares in the company, valued at $2,685,684.96. This represents a 6.86% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 457,858 shares of the company’s stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $200.10, for a total transaction of $91,617,385.80. Following the completion of the transaction, the director owned 2,372,694 shares of the company’s stock, valued at $474,776,069.40. This trade represents a 16.18% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 1,799,688 shares of company stock valued at $379,517,231. 2.90% of the stock is currently owned by corporate insiders.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.